Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AbbVie
Biotech
AbbVie halts development of Dragonfly cancer asset in midflight
AbbVie has terminated a phase 1 trial of the natural killer-cell engager ABBV-303, licensed from Dragonfly as part of an ongoing partnership.
Darren Incorvaia
Oct 29, 2025 1:47pm
Zag Bio emerges with $80M funding for Tregs diabetes candidate
Oct 28, 2025 7:00am
AbbVie flags $2.7B R&D hit to brace investors for lower profit
Oct 6, 2025 3:27am
BMS, Takeda join peers in push to improve AI by pooling data
Oct 1, 2025 10:34am
Genmab discards ADC from $1.8B ProfoundBio buy
Sep 16, 2025 10:33am
AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program
Aug 25, 2025 9:42am
